Literature DB >> 10623641

Identification of tyrosine hydroxylase as an autoantigen in autoimmune polyendocrine syndrome type I.

H Hedstrand1, O Ekwall, J Haavik, E Landgren, C Betterle, J Perheentupa, J Gustafsson, E Husebye, F Rorsman, O Kämpe.   

Abstract

Patients with the autosomal recessively inherited autoimmune polyendocrine syndrome type I (APS I) have autoantibodies directed against several endocrine and nonendocrine organs. In this study a new autoantigen related to this syndrome, tyrosine hydroxylase, was identified in sera from patients with alopecia areata through immunoscreening of a scalp cDNA library. Immunoreactivity against in vitro expressed tyrosine hydroxylase was found in 41 (44%) of the 94 APS I patients studied and this reactivity correlated with the presence of alopecia areata (P = 0.02). These findings further stress the importance of enzymes involved in neurotransmitter biosynthesis as important immune targets in APS I. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623641     DOI: 10.1006/bbrc.1999.1945

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

Review 1.  Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Gregory M Constantine; Michail S Lionakis
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

2.  Pituitary autoantibodies in autoimmune polyendocrine syndrome type 1.

Authors:  Sophie Bensing; Sergueï O Fetissov; Jan Mulder; Jaakko Perheentupa; Jan Gustafsson; Eystein S Husebye; Mikael Oscarson; Olov Ekwall; Patricia A Crock; Tomas Hökfelt; Anna-Lena Hulting; Olle Kämpe
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-10       Impact factor: 11.205

Review 3.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.

Authors:  Kai Kisand; Pärt Peterson
Journal:  J Clin Immunol       Date:  2015-07-05       Impact factor: 8.317

4.  Inhibition of aromatic L-amino acid decarboxylase activity by human autoantibodies.

Authors:  E S Husebye; A S Boe; F Rorsman; O Kämpe; A Aakvaag; T Rygh; T Flatmark; J Haavik
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

5.  Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1.

Authors:  E Helen Kemp; Nikos G Gavalas; Kai J E Krohn; Edward M Brown; Philip F Watson; Anthony P Weetman
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

Review 6.  Autoimmune polyglandular syndrome Type 2: the tip of an iceberg?

Authors:  C Betterle; F Lazzarotto; F Presotto
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

7.  High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome.

Authors:  Peter D Burbelo; Sandra Groot; Marinos C Dalakas; Michael J Iadarola
Journal:  Biochem Biophys Res Commun       Date:  2007-11-29       Impact factor: 3.575

8.  Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors.

Authors:  Anette S B Wolff; Jaanika Kärner; Jone F Owe; Bergithe E V Oftedal; Nils Erik Gilhus; Martina M Erichsen; Olle Kämpe; Anthony Meager; Pärt Peterson; Kai Kisand; Nick Willcox; Eystein S Husebye
Journal:  J Immunol       Date:  2014-09-17       Impact factor: 5.422

9.  Small changes huge impact: the role of protein posttranslational modifications in cellular homeostasis and disease.

Authors:  Tejaswita M Karve; Amrita K Cheema
Journal:  J Amino Acids       Date:  2011-07-21

10.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: insights into genotype-phenotype correlation.

Authors:  Donatella Capalbo; Lucia De Martino; Giuliana Giardino; Raffaella Di Mase; Iolanda Di Donato; Giancarlo Parenti; Pietro Vajro; Claudio Pignata; Mariacarolina Salerno
Journal:  Int J Endocrinol       Date:  2012-10-22       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.